Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity

Biological Psychiatry

Volumn 55, Issue 3, 2004, Pages 320-322

  Vaishnavi, S Neil ^a   Nemeroff, Charles B ^a   Plott, Susan J ^a   Rao, Srinivas G ^b   Kranzler, Jay ^b   Owens, Michael J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cypress Bioscience   (United States)

Author keywords

Human dopamine transporter; Human norepinephrine transporter; Human serotonin transporter; Milnacipran; Monoamine uptake; Transporter binding

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DOPAMINE TRANSPORTER; DULOXETINE; MILNACIPRAN; MONOAMINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; DRUG BINDING; DRUG POTENCY; NORADRENALIN UPTAKE; PRIORITY JOURNAL; SEROTONIN UPTAKE;

EID: 1642441739     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2003.07.006     Document Type: Article

References (15)

1. Anderson I.M. SSRIs versus tricyclic antidepressants in depressed inpatients A meta-analysis of efficacy and tolerability . Depress Anxiety. 7:(suppl 1):1998;11-17.
2. Beique J.-C., Lavoie N., de Montigny C., Debonnel G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 349:1998;129-132.
3. Briley M., Prost J.F., Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol. 11:(suppl 4):1996;9-14.
4. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., Shaw J.L., Thompson L., Nelson D.T., et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 25:2001;871-880.
5. Engleman E.A., Perry K.W., Mayle D.A., Wong D.T. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology. 12:1995;287-295.
6. Gilmor M.L., Owens M.J., Nemeroff C.B. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 159:2002;1702-1710.
7. Mongeau R., Weiss M., de Montigny C., Blier P. Effect of acute, short- and long-term milnacipran administration on rat locus caeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology. 37:1998;905-918.
8. Moret C., Briley M. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J Neurochem. 69:1997;815-822.
9. Moret C., Charveron M., Finberg J.P., Couzinier J.P., Briley M. Biochemical profile of midalcipran (F 2207),1-phenyl-1-diethyl-aminocarbonyl-2- aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology. 24:1985;1211-1219.
10. Owens M.J., Knight D.L., Nemeroff C.B. Second-generation SSRIs Human monoamine transporter binding profile of escitalopram and R-fluoxetine . Biol Psychiatry. 50:2001;345-350.
11. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 283:1997;1305-1322.
12. Palmier C., Puozzo C., Lenehan T., Briley M. Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran. Eur J Clin Pharmacol. 37:1989;235-238.
13. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 340:1997;249-258.
14. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin uptake inhibitors in resistant depression. Br J Psychiatry. 178:2001;234-241.
15. Turcotte J.E., Debonnel G., de Montigny C., Hebert C., Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 24:2001;511-521.